Xenograft studies for the Marine Fungi Consortium
A group of eleven institutions from seven different countries has jointly set up a consortium of experts to cooperatively conduct the project 'MARINE FUNGI', which received funding from the European Commission under the 'Seventh Framework Programme' (FP7). The project is coordinated by the 'Helmholtz Zentrum für Ozeanforschung (GEOMAR)' Kiel, Germany.
The aim of MARINE FUNGI is to demonstrate the sustainable exploitation of under-utilised marine natural resources, namely fungi isolated from various marine sources. As well as demonstrating the efficient and scalable production of marine natural products, the project has been exploring marine fungi as a source of useful new natural compounds, with a therapeutic focus on the development of novel anti-cancer compounds. The scope of the project includes the characterization of the most promising compounds to the stage of in vivo proof of concept of anti-tumour efficacy.
Compounds with desirable characteristics and confirmed dose dependent in vitro biological activity in the context of the NCI60 collection of cancer cell lines1, will be subject to increasingly detailed assessment in higher content/value assays. The best compounds will be selected on the basis of in vitro compound efficacy performance, appropriate pharmaceutical potential and in vivo pharmacokinetic (PK) profiles. Following in vivo PK studies and maximum tolerable dose assessment, up to 5 promising compounds will be analysed in Xenograft mouse models.
The objective is to define and document the requirements for the determination of the anti-tumour efficacy of selected compounds in Xenograft mouse model studies of up to 5 compounds for the MARINE FUNGI Consortium.
Deadline
Die Frist für den Eingang der Angebote war 2013-12-06.
Die Ausschreibung wurde veröffentlicht am 2013-11-27.
Wer?
Wie?
Geschichte der Beschaffung
| Datum |
Dokument |
| 2013-11-27
|
Auftragsbekanntmachung
|